<p>|Recommendation/statement|PICO question informing recommendation and discussion|Level of evidence|
|---|---|---|
|Remission induction for active, severe disease| | |
|Recommendation: For patients with active, severe GPA/MPA, we conditionally recommend treatment with rituximab over cyclophosphamide for remission induction.|4, 5, 6|Very low to moderate|
|Recommendation: In patients with GPA/MPA with active glomerulonephritis, we conditionally recommend against the routine addition of plasma exchange to remission induction therapy.|34|Low to high|
|Recommendation: In patients with active, severe GPA/MPA with alveolar hemorrhage, we conditionally recommend against adding plasma exchange to remission induction therapies.|35|Low to high|
|Ungraded position statement: For patients with active, severe GPA/MPA, either IV pulse GCs or high-dose oral GCs may be prescribed as part of initial therapy.|2|Very low to moderate|